Item 1.01. Entry into a Material Definitive
Agreement.
On January 24, 2022, Star Equity Holdings, Inc.
(the “Company”) closed its previously announced firm commitment underwritten public offering (the “Offering”)
in which, pursuant to the underwriting agreement (the “Underwriting Agreement”) entered into by and between the Company and
Maxim Group LLC (“Maxim”), as representative of the underwriters, dated January 19, 2022, the Company issued and sold (A)(i)
9,175,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) an aggregate
of 325,000 pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 325,000 shares of Common Stock,
and (iii) an aggregate of 9,500,000 common stock purchase warrants (the “Firm Purchase Warrants”) to purchase up to 9,500,000
shares of Common Stock and (B) at the election of Maxim, (i) up to an additional 1,425,000 shares of Common Stock (the “Option Shares”)
and/or (ii) up to an additional 1,425,000 shares of common stock purchase warrants (the “Option Purchase Warrants”, and together
with the Firm Purchase Warrants, the “Warrants”). The Offering price was $1.49 per share of Common Stock and $0.01 per accompanying
Warrant (for a combined Offering price of $1.50). Pursuant to the Underwriting Agreement, the Company granted to Maxim an option for a
period of 45 days (the “Over-Allotment Option”) to purchase the Option Shares and/or the Option Purchase Warrants. Effective
as of the closing of the Offering, Maxim also partially exercised the Over-Allotment Option for the purchase of 1,425,000 Warrants for
a price of $0.01 per Warrant. The Underwriting Agreement contained customary representations, warranties, and agreements by the Company,
customary conditions to closing, indemnification obligations of the Company and Maxim (including for liabilities under the Securities
Act of 1933, as amended) and certain other obligations.
The net proceeds to the Company from the Offering
(including the partial exercise of the Over-Allotment Option) were approximately $12.8 million, after deducting the fees and commissions
and estimated Offering expenses payable by the Company, and excluding any proceeds the Company may receive upon exercise of the Warrants.
The Company currently intends to use the net proceeds to pursue organic growth initiatives and fund potential acquisitions, and for working
capital and other general corporate purposes. The Company will have broad discretion in determining how the proceeds of the Offering will
be used, and its discretion is not limited by the aforementioned possible uses.
The shares of Common Stock and Warrants were issued
in the Offering pursuant to the Company’s registration statement on Form S-1, as amended (File No. 333-261957) (the “Registration
Statement”), which was declared effective by the U.S. Securities and Exchange Commission (the “Commission”) on January
19, 2022. The Registration Statement also registered the Maxim Warrant (defined below) and the shares of Common Stock issuable upon exercise
of the Maxim Warrant and the Warrants sold in the Offering. The Common Stock is listed on The NASDAQ Global Market; however, the Warrants
will not be listed on The NASDAQ Global Market, any other national securities exchange or any other nationally recognized trading system.
Maxim acted as the Company’s sole book-running
manager in connection with the Offering. In connection with Maxim’s services, Maxim received an underwriting discount equal to 7%
of the gross proceeds of the offering. The Company also agreed to pay Maxim an expense allowance of up to $90,000 for fees and expenses
of legal counsel and other out-of-pocket expenses. In addition, the Company issued to Maxim a warrant to purchase up to 1,425,000 shares
of Common Stock (the “Maxim Warrant”). The Maxim Warrant has an exercise price equal to $1.65 per share of Common Stock, which
is equal to 110% of the price per share for the shares of Common Stock sold in the Offering, and is exercisable for five years from the
date of issuance.
The Warrants are immediately exercisable upon
issuance at a price of $1.50 per share of Common Stock, subject to adjustment in certain circumstances, and will expire on January 24,
2027 (five years from the date of issuance). No fractional shares of Common Stock will be issued in connection with the exercise of a
Warrant. In lieu of fractional shares, the Company will round up to the next whole share. The Warrants also provide that in the event
of a fundamental transaction the Company is required to cause any successor entity to assume its obligations under the Warrants. In addition,
the holder of the Warrant is entitled to receive upon exercise of the Warrant the kind and amount of securities, cash or property that
the holder would have received had the holder exercised the Warrant immediately prior to such fundamental transaction. In addition, the
Warrants will be exercisable on a cashless basis if no registration statement registering the shares of Common Stock underlying the Warrants
is effective according to the formula set forth in the Warrant. American Stock Transfer & Trust Company, LLC (“AST”) will
serve as the agent for the Company with respect to the Warrants pursuant to a Warrant Agent Agreement entered into by AST and the Company
on January 24, 2022.
A holder of Warrants will not have the right to
exercise any portion of its Warrants if such holder (together with its affiliates) would beneficially own in excess of 4.99% of the number
of shares of the Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined
in accordance with the terms of the Warrants. However, any exercise of the Warrants which would result in a holder beneficially owning
more than 4.99% of the Company’s outstanding shares of Common Stock will be subject to the Company’s consent, provided that
any beneficial ownership in excess of the 4.99% threshold will not take effect until 61 days following notice to, and approval by, the
Company. The Company may, in our sole discretion, waive the 4.99% ownership limitation in connection with the Offering with respect to
one or more potential purchasers.
The foregoing descriptions of the Underwriting
Agreement, the Maxim Warrant, the Warrants and the Warrant Agent Agreement are not complete and are qualified in their entirety by reference
to the full text of the Underwriting Agreement, the form of Pre-Funded Warrant, the form of Warrant, and the form of Investor Agreement,
copies of which are included as Exhibit 1.1, Exhibit 4.1, Exhibit 4.2 and Exhibit 4.3, respectively, to this Current Report on Form 8-K
and are incorporated herein by reference. The provisions of the Underwriting Agreement, including the representations and warranties contained
therein, are not for the benefit of any party other than the parties to such agreement and are not intended as a document for investors
and the public to obtain factual information about the current state of affairs of the parties to that document. Rather, investors and
the public should look to other disclosures contained in the Company’s filings with the Commission.